SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ambalal Sarabhai touches roof as its JV receives CDSCO license to manufacture SARAGENE Dengue Test Kit

17 Sep 2021 Evaluate

Ambalal Sarabhai Enterprises is locked its upper circuit limit at Rs. 31.00, up by 1.45 points or 4.91% from its previous closing of Rs. 29.55 on the BSE.

The scrip opened at Rs. 31.00 and has touched a high and low of Rs. 31.00 and Rs. 31.00 respectively. So far 143776 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 65.00 on 28-May-2021 and a 52 week low of Rs. 16.55 on 25-Sep-2020.

Last one week high and low of the scrip stood at Rs. 30.20 and Rs. 28.40 respectively. The current market cap of the company is Rs. 237.56 crore.

The promoters holding in the company stood at 30.76%, while Non-Institutions held 69.24%.

CoSara Diagnostics, a Joint Venture (JV) of a subsidiary of Ambalal Sarabhai Enterprises and Co-Diagnostics, Inc, has obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell SARAGENE Dengue Test Kit. The tests are now available for sale.

SARAGENE Dengue Test Kit is an in vitro diagnostic test, based on Real-Time Polymerase Chain Reaction Technology. Test utilizes Co-Diagnostics' patented CoPrimers technology (Satterfield, 2014) (Poritz & Ririe, 2014). It tests for the presence or absence of ribonucleic acid (RNA) of Dengue (Type 1, 2 4) in serum or plasma from patients suspected of dengue viral infection.

Ambalal Sarabhai Enterprises is engaged in manufacturing and marketing of pharmaceutical products, bulk drugs, industrial chemicals, detergents, toiletries, electronics, engineering products, paper, glass and plastic containers and packaging materials.

Ambalal Sarabhai Ent Share Price

31.07 -0.26 (-0.83%)
06-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1850.40
Dr. Reddys Lab 1310.50
Cipla 1365.25
Zydus Lifesciences 940.00
Lupin 2442.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×